JBIO

Business Context and Reporting Period

Company: Aerovate Therapeutics, Inc. (Note: The input metadata references "Jade Biosciences, Inc." as the company name, but the filing text identifies the registrant as Aerovate Therapeutics, Inc., which is entering into a merger with Jade Biosciences, Inc.)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal year ended December 31, 2024

Aerovate is a biopharmaceutical company that halted the development of its sole product candidate, AV-101 (an inhaled formulation of imatinib for pulmonary arterial hypertension), in June 2024 after Phase 2b clinical trial results failed to meet primary endpoints. Consequently, the company terminated approximately 92% of its workforce and is currently exploring strategic alternatives. On October 30, 2024, Aerovate entered into a definitive Merger Agreement with Jade Biosciences, Inc. The transaction involves a reverse merger structure where Jade will become a subsidiary of Aerovate, followed by a cash dividend to Aerovate's pre-merger stockholders.

Key Financial Metrics

Note: The company has no debt obligations as of December 31, 2024.

Material Changes vs. Prior Period

• Clinical Trial Failure: In June 2024, the company announced negative topline results for AV-101, leading to the immediate shutdown of Phase 3 trials and the long-term extension study. This marked a cessation of all product development activities.
• Workforce Reduction: The company implemented a Workforce Reduction Plan, terminating 47 individuals (approximately 92% of the workforce) by year-end. This resulted in one-time severance costs of approximately $6.7 million.
• Expense Reduction: Total operating expenses decreased by $6.8 million year-over-year, driven primarily by a $11.0 million reduction in Research and Development (R&D) costs due to the trial shutdown. General and Administrative (G&A) expenses increased by $4.2 million, largely due to legal and consulting fees related to the strategic review and merger.
• Liquidity Position: While total liquidity decreased from $122.4 million in 2023 to $78.6 million in 2024, the company maintains sufficient cash to fund operations for at least 12 months pending the merger.

Guidance, Outlook, and Risks

Merger with Jade Biosciences: The primary strategic focus is the consummation of the merger with Jade Biosciences, Inc. Key terms include:

• Cash Dividend: Aerovate expects to declare a cash dividend of approximately $65.0 million to pre-merger stockholders upon closing.
• Concurrent Investment: Jade has secured a concurrent investment of approximately $300.0 million from existing and new investors, which will fund the combined entity.
• Ownership Structure: Post-merger, former Aerovate stockholders are expected to own approximately 1.6% of the combined company on a fully diluted basis, while Jade's pre-closing securityholders (excluding the new financing) will own approximately 34.0%.

Outlook: The company does not intend to resume development of AV-101 or pursue new product candidates independently. Future operations are entirely dependent on the successful closing of the merger.

Key Risks:

• Merger Failure: If the merger is not completed, the board may pursue dissolution and liquidation. The amount of cash available for distribution would depend on the timing and remaining liabilities.
• Termination Fees: If the merger agreement is terminated under specified circumstances, Aerovate may be required to pay Jade a termination fee of $2.34 million, or Jade may pay Aerovate $5.25 million.
• Intellectual Property: The company has begun abandoning its patent estate related to AV-101 and is no longer prosecuting patent applications.

Investor Verification Checklist

• Merger Approval Status: Verify if the merger has received requisite stockholder approval from both Aerovate and Jade, as well as Nasdaq listing approval.
• Concurrent Investment Closing: Confirm that the $300.0 million concurrent investment by Jade has been fully executed and funds are available to the combined entity.
• Dividend Timing and Amount: Monitor announcements regarding the record date and payment of the expected $65.0 million cash dividend to Aerovate shareholders.
• Liquidity Runway: Assess the company's cash burn rate in the event of a merger delay to ensure the $78.6 million cash balance remains sufficient for operations.
• Severance Liability: Confirm the payout schedule for the remaining $2.9 million in accrued severance liabilities associated with the workforce reduction.